Table 3 Multivariate analysis.

From: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR

Outcomes

N

HR (95% CI)

P value

Overall survival

 Main effect

   Chemotherapy

261

Reference

 

   Allogeneic HCT

217

2.00 (1.50–2.66)

<0.001

Body mass index (kg/m2)

  <30

332

Reference

 

  ≥30

146

2.17 (1.63–2.89)

<0.001

Disease-free survival

 Main effect

   Chemotherapy

261

Reference

 

   Allogeneic HCT

215

1.62 (1.25–2.12)

<0.001

Body mass index (kg/m2)

  <30

331

Reference

 

  ≥30

145

1.97 (1.51–2.57)

<0.001

Relapse

 Allogeneic HCT vs. chemotherapy ≤ 15 months after CR1

 

1.78 (1.10–2.88)

0.02

 Allogeneic HCT vs. chemotherapy > 15 months after CR1

 

0.34 (0.19–0.62)

<0.001

Body mass index (kg/m2)

  <30

331

Reference

 

  ≥30

145

1.84 (1.31–2.59)

<0.001

Non-relapse mortality

 Main effect

   Chemotherapy

261

Reference

 

   Allogeneic HCT

215

5.41 (3.23–9.06)

<0.001

Body mass index (kg/m2)

  <30

331

Reference

 

  ≥30

145

2.10 (1.37–3.23)

<0.001

Back to article page